Axxcess Wealth Management LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 14.2% during ...

Crossmark Global Holdings Inc. lessened its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 16.0% during the ...

Analysts said the findings complicate the outlook for a U.S. launch of Boston Scientific's aortic valve replacement device.

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial ...

versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system, selected at the discretion of the implanting physician.

versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system. The composite rate of all-cause mortality, stroke, or ...

WASHINGTON, D.C.—Boston Scientific’s long-awaited transcatheter aortic heart valve missed its mark in ... choice of either Edwards Lifesciences’ Sapien 3 or Medtronic’s Evolut family.

The trial, which compared the second-generation ACURATE neo2 valve to a control valve—either the SAPIEN™ valve or the Evolut™ transcatheter aortic valve—did not meet the prespecified ...

At 1 year, the combined rate of all-cause mortality, stroke, or rehospitalization was 16.16% in patients treated with Acurate neo2 and 9.53% among those treated with valves from the Evolut (Medtronic) ...